The largest genetic analysis of abdominal aortic aneurysm (AAA) carried out to date has identified almost 100 new risk variants linked to the disorder. The study also highlighted a possible therapeutic target for this pathology that, at the moment, has no treatment. AAA affects 4% of people over 65 years of age in the U.S. and causes 41,000 deaths per year. The incidence is three to four times higher in men than in women. Read More
One of the main issues encountered by therapeutic antibodies for the treatment of neurodegenerative disorders such as Alzheimer’s disease (AD) is the difficulty of crossing the blood-brain barrier (BBB) to access the central nervous system. To overcome these problems, several attempts have been made using endothelial transmembrane proteins where antibodies can bind. One of these efforts involves transferrin receptor 1 (TfR1). Read More
F-box/WD repeat-containing protein 7 (FBXW7) is known to regulate the protein stability of key metabolic transcription factors, including the major transcriptional regulator of lipid biosynthesis, SREBP1, the overactivation of which has been previously linked to elevated lipogenesis. Read More
The Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford have launched a new project to initiate early development of prototype vaccines against the Junín virus, selected as an exemplar of the Arenavirus family which is responsible for multiple deadly hemorrhagic fevers with epidemic and pandemic potential. Read More
Uniquest Pty Ltd. has synthesized tyrosine-protein kinase SYK inhibitors reported to be useful for the treatment of allergy, cancer, fungal infections, rheumatoid arthritis, osteoporosis, liver, lung and periodontal diseases, among others. Read More
Angiex Inc. has received FDA clearance of its IND application for AGX-101, a novel TM4SF1-directed antibody-drug conjugate (ADC) being developed for the treatment of solid cancers. Read More
Researchers from Yunnan University of Traditional Chinese Medicine have reported the discovery of novel antifungal compounds against Candida albicans. Read More
Brenig Therapeutics Inc. has disclosed leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of Parkinson’s disease, among others. Read More
The National Institute of Allergy and Infectious Diseases (NIAID) is set to conduct a phase I trial with Tonix Pharmaceuticals Holding Corp.’s TNX-1800 (recombinant horsepox virus, live vaccine), a vaccine candidate to protect against COVID-19. Read More
Alesta Therapeutics BV has identified eukaryotic translation initiation factor 2-α kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer. Read More
KAT6A is a histone acetyltransferase involved in transcriptional co-activation, proliferation and differentiation of hematopoietic progenitor and stem cells. Mutations and translocations in KAT6A are oncogenic drivers in hematological malignancies. Read More
Corbus Pharmaceuticals Holding Inc. has described cannabinoid CB1 receptor antagonists or inverse agonists reported to be useful for the treatment of cancer, dyslipidemia, diabetes, obesity, cardiovascular, inflammatory and liver diseases. Read More
New and updated preclinical data presented at the Society for Immunotherapy of Cancer congress in San Diego, by: Akeso, Antengene, Asher Biotherapeutics, Bioinvent International, Carisma Therapeutics, Catalym, Coeptis Therapeutics, Context Therapeutics, Corbus Pharmaceuticals, Gracell Biotechnologies, Lyell Immunopharma. Read More
